H.C. Wainwright lowered the firm’s price target on Edesa Biotech to $21 from $70 and keeps a Buy rating on the shares. The firm cites the reverse stock split for the target change and believes the shares represent an attractive value proposition.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on EDSA: